Decision-grade research for healthcare and life sciences, commercial, not clinical. Healthtech, medtech, pharma commercial, providers, payors, and the vendors that serve them.
What's different about healthcare B2B research
- Multi-stakeholder buying. Clinician, administrator, procurement, finance and often a payor all weigh in. Research has to read all of them.
- Evidence culture. Healthcare buyers expect evidence-based argument. Sloppy research gets dismissed faster than in most sectors.
- Long cycles. Provider procurement cycles run 12–36 months. Research design captures cycle state, not just snapshot opinion.
- Regulatory framing. Almost every decision sits inside a regulatory and reimbursement context. Research treats this as foreground, not background.
Where we work in healthcare
- Healthtech and digital health. ICP, persona, GTM and willingness-to-pay research for B2B healthtech sellers.
- Medtech and devices. Market sizing, GTM, partnership work; commercial diligence on medtech targets.
- Pharma commercial. HCP and administrator research; competitive intelligence; partnership and JV work.
- Hospital and provider systems. Vendor-selection research, voice-of-customer programmes, partnership research.
- Payors and insurers. Buyer research; partnership and category research for vendors selling into payors.
- Life sciences tools and services. ICP, persona and GTM research for the broader life sciences ecosystem.